S100A9 and glioblastoma: A proteomic screening for potential protein patterns in glioblastoma patients serum revealed the alteration of several proteins (Bone morphogenetic protein 2 (BMP2), Platelet factor 4 (PLF4), C-X-C motif chemokine 10 (CXL10), Protein S100-A8 (S10A8), Protein S100-A9 (S10A9), Beta-Ala-His dipeptidase (CNDP1), Ferritin light chain (FRIL) and Heat shock 70 kDa protein family (HS71A, HS71B)) that have the potential to be used as biomarkers for a glioblastoma diagnosis or to be investigated as therapeutic targets [18,46,47].